ID   NCI-H2228
AC   CVCL_1543
SY   H2228; H-2228; NCIH2228
DR   BTO; BTO:0006023
DR   CLO; CLO_0008067
DR   EFO; EFO_0002284
DR   AddexBio; C0016017/4969
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5935
DR   BCRJ; 0330
DR   BioSample; SAMN03473167
DR   BioSample; SAMN10987779
DR   cancercelllines; CVCL_1543
DR   CCRID; 3101HUMSCSP5001
DR   Cell_Model_Passport; SIDM00729
DR   ChEMBL-Cells; CHEMBL3308120
DR   ChEMBL-Targets; CHEMBL1075536
DR   CLS; 305125
DR   Cosmic; 687816
DR   Cosmic; 897513
DR   Cosmic; 903617
DR   Cosmic; 930491
DR   Cosmic; 1146905
DR   Cosmic; 1609517
DR   Cosmic; 1612226
DR   Cosmic; 1995564
DR   Cosmic-CLP; 687816
DR   DepMap; ACH-000447
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 687816
DR   GEO; GSM434317
DR   GEO; GSM513959
DR   GEO; GSM514344
DR   GEO; GSM794361
DR   GEO; GSM827512
DR   GEO; GSM887415
DR   GEO; GSM888494
DR   GEO; GSM1374727
DR   GEO; GSM1670226
DR   IARC_TP53; 27190
DR   IGRhCellID; NCIH2228
DR   LiGeA; CCLE_800
DR   LINCS_LDP; LCL-1652
DR   PharmacoDB; NCIH2228_1081_2019
DR   PRIDE; PXD011315
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1543
DR   PubChem_Cell_line; CVCL_1543
DR   Wikidata; Q54907944
RX   DOI=10.1101/2022.06.08.495301;
RX   PubMed=8626706;
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=18083107;
RX   PubMed=18594010;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22334442;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=23344087;
RX   PubMed=24675041;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=30710758;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   HLA typing: A*02:01,03:01; B*07:02,38:01; C*07:02,12:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK; Note=E6A20 v3 fusion (PubMed=18594010; DOI=10.1101/2022.06.08.495301; DepMap).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 9655; PTPN3; Name(s)=ALK-PTPN3 (PubMed=22334442).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.1%; Native American=0.08%; East Asian, North=0.5%; East Asian, South=0.06%; South Asian=0.85%; European, North=65.31%; European, South=33.09% (PubMed=30894373).
CC   Misspelling: HC2228; Cosmic=1612226.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): AddexBio; ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 11,13
ST   D18S51: 16
ST   D19S433: 14,15
ST   D21S11: 28,30
ST   D2S1338: 17
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 13
ST   FGA: 21,22
ST   Penta D: 11,13
ST   Penta E: 11,16
ST   TH01: 7,8
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 42
//
RX   DOI=10.1101/2022.06.08.495301;
RA   Licciardello M.P., Zhang C., Le A.T., Doebele R.C., Clarke P.A.,
RA   Workman P.;
RT   "Loss of spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90
RT   inhibitors.";
RL   bioRxiv 2022:06.08.495301-06.08.495301(2022).
//
RX   PubMed=8626706; DOI=10.1074/jbc.271.19.11477;
RA   Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M.,
RA   Grimley C., Battey J., Mulshine J.L., Cuttitta F.;
RT   "Insulin-like growth factor expression in human cancer cell lines.";
RL   J. Biol. Chem. 271:11477-11483(1996).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H.,
RA   Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P.,
RA   Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q.,
RA   Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
//
RX   PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168;
RA   Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E.,
RA   Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J.,
RA   Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P.,
RA   Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.;
RT   "EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung
RT   cancer.";
RL   Clin. Cancer Res. 14:4275-4283(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22334442; DOI=10.1002/gcc.21945;
RA   Jung Y., Kim P., Jung Y., Keum J., Kim S.-N., Choi Y.S., Do I.-G.,
RA   Lee J., Choi S.-J., Kim S., Lee J.-E., Kim J., Lee S., Kim J.;
RT   "Discovery of ALK-PTPN3 gene fusion from human non-small cell lung
RT   carcinoma cell line using next generation RNA sequencing.";
RL   Genes Chromosomes Cancer 51:590-597(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0;
RA   Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L.,
RA   Chung D.H., Heo D.S.;
RT   "Heterogeneity of genetic changes associated with acquired crizotinib
RT   resistance in ALK-rearranged lung cancer.";
RL   J. Thorac. Oncol. 8:415-422(2013).
//
RX   PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846;
RA   Friboulet L., Li N.-X., Katayama R., Lee C.C., Gainor J.F., Crystal A.S.,
RA   Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C.,
RA   Li J., Kasibhatla S., Sun F., Sun X.-Y., Hua S., McNamara P., Mahmood S.,
RA   Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T.,
RA   Engelman J.A.;
RT   "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small
RT   cell lung cancer.";
RL   Cancer Discov. 4:662-673(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30710758; DOI=10.1016/j.jprot.2019.01.018;
RA   Bottger F., Schaaij-Visser T.B.M., de Reus I., Piersma S.R.,
RA   Pham T.V., Nagel R., Brakenhoff R.H., Thunnissen E., Smit E.F.,
RA   Jimenez C.R.;
RT   "Proteome analysis of non-small cell lung cancer cell line secretomes
RT   and patient sputum reveals biofluid biomarker candidates for
RT   cisplatin response prediction.";
RL   J. Proteomics 196:106-119(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//